vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $124.7M, roughly 1.3× SMITH & WESSON BRANDS, INC.). SMITH & WESSON BRANDS, INC. runs the higher net margin — 1.5% vs -82.0%, a 83.5% gap on every dollar of revenue. On growth, SMITH & WESSON BRANDS, INC. posted the faster year-over-year revenue change (-3.9% vs -22.7%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $-36.6M). Over the past eight quarters, SMITH & WESSON BRANDS, INC.'s revenue compounded faster (-4.8% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
PTCT vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $124.7M |
| Net Profit | $-135.0M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | -43.3% | 3.3% |
| Net Margin | -82.0% | 1.5% |
| Revenue YoY | -22.7% | -3.9% |
| Net Profit YoY | -104.8% | -53.6% |
| EPS (diluted) | $-1.63 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $164.7M | $124.7M | ||
| Q3 25 | $211.0M | $85.1M | ||
| Q2 25 | $178.9M | $140.8M | ||
| Q1 25 | $1.2B | $115.9M | ||
| Q4 24 | $213.2M | $129.7M | ||
| Q3 24 | $196.8M | $88.3M | ||
| Q2 24 | $186.7M | $159.1M | ||
| Q1 24 | $210.1M | $137.5M |
| Q4 25 | $-135.0M | $1.9M | ||
| Q3 25 | $15.9M | $-3.4M | ||
| Q2 25 | $-64.8M | $8.6M | ||
| Q1 25 | $866.6M | $2.1M | ||
| Q4 24 | $-65.9M | $4.5M | ||
| Q3 24 | $-106.7M | $-1.9M | ||
| Q2 24 | $-99.2M | $27.9M | ||
| Q1 24 | $-91.6M | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | -43.3% | 3.3% | ||
| Q3 25 | 1.4% | -3.5% | ||
| Q2 25 | -19.5% | 9.3% | ||
| Q1 25 | 82.5% | 4.1% | ||
| Q4 24 | -76.2% | 5.8% | ||
| Q3 24 | -27.7% | -1.7% | ||
| Q2 24 | -21.5% | 17.4% | ||
| Q1 24 | -21.6% | 8.2% |
| Q4 25 | -82.0% | 1.5% | ||
| Q3 25 | 7.5% | -4.0% | ||
| Q2 25 | -36.3% | 6.1% | ||
| Q1 25 | 73.7% | 1.8% | ||
| Q4 24 | -30.9% | 3.5% | ||
| Q3 24 | -54.2% | -2.1% | ||
| Q2 24 | -53.1% | 17.5% | ||
| Q1 24 | -43.6% | 5.7% |
| Q4 25 | $-1.63 | $0.04 | ||
| Q3 25 | $0.20 | $-0.08 | ||
| Q2 25 | $-0.83 | $0.19 | ||
| Q1 25 | $10.04 | $0.05 | ||
| Q4 24 | $-0.85 | $0.10 | ||
| Q3 24 | $-1.39 | $-0.04 | ||
| Q2 24 | $-1.29 | $0.60 | ||
| Q1 24 | $-1.20 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $363.2M |
| Total Assets | $2.9B | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | $22.4M | ||
| Q3 25 | $1.7B | $18.0M | ||
| Q2 25 | $2.0B | $25.2M | ||
| Q1 25 | $2.0B | $26.7M | ||
| Q4 24 | $1.1B | $39.1M | ||
| Q3 24 | $1.0B | $35.5M | ||
| Q2 24 | $1.1B | $60.8M | ||
| Q1 24 | $884.8M | $47.4M |
| Q4 25 | $-205.3M | $363.2M | ||
| Q3 25 | $-155.8M | $364.4M | ||
| Q2 25 | $-206.5M | $372.5M | ||
| Q1 25 | $-185.8M | $366.9M | ||
| Q4 24 | $-1.1B | $371.5M | ||
| Q3 24 | $-1.1B | $380.0M | ||
| Q2 24 | $-980.2M | $399.9M | ||
| Q1 24 | $-893.9M | $376.4M |
| Q4 25 | $2.9B | $548.6M | ||
| Q3 25 | $2.6B | $554.6M | ||
| Q2 25 | $2.6B | $559.6M | ||
| Q1 25 | $2.7B | $578.9M | ||
| Q4 24 | $1.7B | $587.4M | ||
| Q3 24 | $1.8B | $571.3M | ||
| Q2 24 | $1.9B | $577.4M | ||
| Q1 24 | $1.8B | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $27.3M |
| Free Cash FlowOCF − Capex | $-36.6M | $16.3M |
| FCF MarginFCF / Revenue | -22.3% | 13.1% |
| Capex IntensityCapex / Revenue | 1.4% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | $27.3M | ||
| Q3 25 | $-66.3M | $-8.1M | ||
| Q2 25 | $-58.3M | $40.8M | ||
| Q1 25 | $870.1M | $-9.8M | ||
| Q4 24 | $-30.0M | $-7.4M | ||
| Q3 24 | $-77.0M | $-30.8M | ||
| Q2 24 | $-71.5M | $43.7M | ||
| Q1 24 | $70.8M | $25.2M |
| Q4 25 | $-36.6M | $16.3M | ||
| Q3 25 | $-69.7M | $-12.4M | ||
| Q2 25 | $-59.6M | $33.5M | ||
| Q1 25 | $868.4M | $-16.1M | ||
| Q4 24 | $-33.8M | $-10.7M | ||
| Q3 24 | $-77.5M | $-35.5M | ||
| Q2 24 | $-78.8M | $38.2M | ||
| Q1 24 | $61.2M | $7.0M |
| Q4 25 | -22.3% | 13.1% | ||
| Q3 25 | -33.1% | -14.6% | ||
| Q2 25 | -33.3% | 23.8% | ||
| Q1 25 | 73.8% | -13.9% | ||
| Q4 24 | -15.8% | -8.3% | ||
| Q3 24 | -39.4% | -40.2% | ||
| Q2 24 | -42.2% | 24.0% | ||
| Q1 24 | 29.1% | 5.1% |
| Q4 25 | 1.4% | 8.8% | ||
| Q3 25 | 1.6% | 5.0% | ||
| Q2 25 | 0.7% | 5.2% | ||
| Q1 25 | 0.1% | 5.4% | ||
| Q4 24 | 1.8% | 2.5% | ||
| Q3 24 | 0.3% | 5.3% | ||
| Q2 24 | 4.0% | 3.5% | ||
| Q1 24 | 4.6% | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | -4.17× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | 1.00× | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
